Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 Data from the ...

Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.

In patients with ulcerative colitis who had endoscopic healing, achieving transmural healing was associated with longer relapse-free survival. Women and those who had received multiple advanced ...

Floris de Voogd, MD; Elsa A. van Wassenaer, MD; Aart Mookhoek, MD, PhD; Steven Bots, MD; Sara van Gennep, MD; Mark Löwenberg, MD, PhD; Geert R. D’Haens, MD, PhD ...

Artificial intelligence (AI) is used in ulcerative colitis to assist in the assessment, monitoring, and management of disease. To explain how this technology is being applied in the clinical setting, ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well ...

The diagnosis of ulcerative colitis (UC) is based on clinical evaluation and medical history and confirmed through laboratory, radiologic, endoscopic and histologic findings. Before making the ...

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...